Metselex, inc.
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07J (Steroids).
The verdict
According to USPTO PatentsView, Metselex ranks #48,707 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.
- #48,707
- of 49,997 US assignees by volume
- 17th percentile
- by Innovation Score (25.2/100)
- 7.4
- avg claims per patent
- -33%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R48707 · US Corporation #48,707 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL
- GRANTS-MICRO 5 grants
- BOTTOM-DECILE #48,707/49,997
- PHOTO-FINISH Metactive Medical
- CPC-NARROW C07J · 5 areas
- INNOV-THIN 25.2/100
- CLAIMS-SPARSE 7.4 claims/avg
- TYPE-USCORP US Corporation
- VEL-DOWN -33% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Metactive Medical, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Metselex’s 25.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Metselex
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Metselex · this assignee 25
Metselex · this assignee
25 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Metselex's Innovation Score is 25.2/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Metselex?
Each dot is one of Metselex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Metselex’s own 7.4 claims/patent is at or below the 17.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Metselex's grants concentrate
Metselex, inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07J (Steroids). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2018. By volume, Metselex sits between Metactive Medical, Inc. and Mewt LLC.
Metselex's three-year grant acceleration
Metselex, inc. shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Metselex's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Metactive Medical
Metactive Medical, Inc.
5 patents
- Metadata
Metadata, Inc.
5 patents
- Metall + Plastic
Metall + Plastic GmbH
5 patents
- Metirionic
Metirionic GmbH
5 patents
- Metso Finland Oy
Metso Finland Oy
5 patents
- Metsä Board Oyj
Metsä Board Oyj
5 patents
- Metzner Holding
Metzner Holding GmbH
5 patents
- Mewt
Mewt LLC
5 patents
- Metselex ◀
Metselex, inc.
5 patents
What this shows Metselex holds 5 patents at rank #48,840, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Metselex
By rank, the assignees closest to #48,840 in granted patent volume.
Leaders in C07J (Steroids)
Other assignees with the most granted patents in Metselex's primary technology class.
- Sage Therapeutics, Inc. 85 in class
- Intercept Pharmaceuticals, Inc. 39 in class
- Reata Pharmaceuticals Holdings, LLC 30 in class
- Enanta Pharmaceuticals, Inc. 20 in class
- Pop Test Oncology LLC 18 in class
- Brigham Young University 16 in class
- Bayer Intellectual Property GmbH 12 in class
- Arcturus Therapeutics, Inc. 12 in class
Metselex's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
25 17th percentile higher than 17% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 2 | 40.0% |
| 2018 | 1 | 20.0% |
| 2021 | 1 | 20.0% |
| 2024 | 1 | 20.0% |
Which technologies does Metselex, inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Metselex, inc.'s patent record in context - here's where to go next.
- Metselex, inc.'s lead technology class is C07J (Steroids), 100% of its portfolio - see every assignee active in that class. Explore C07J
- Ranked #48,707 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Metselex, inc. against Metactive Medical, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 25.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.